The role of nutrition and nutraceuticals in the prevention of chronic diseases

Saule Iskakova [1,*] *Kamila* Karimsakova [2]

[1] Scientific research institute of preventive medicine named after Academician Y.D. Dalenov, Astana Medical Universit, Kazakhstan, Astana

Abstract. Chronic diseases such as cardiovascular disorders, diabetes, cancer, and neurodegenerative conditions represent a major global health burden, with lifestyle factors playing a crucial role in their onset and progression. Nutrition, alongside emerging nutraceutical compounds, has garnered significant attention as a preventive strategy due to their potential to modulate metabolic pathways, reduce inflammation, and enhance antioxidant defenses. This review explores the role of dietary patterns and bioactive nutraceuticals—including vitamins, minerals, polyphenols, omega-3 fatty acids, and probiotics—in mitigating risk factors and delaying the progression of chronic diseases. Evidence from epidemiological studies, clinical trials, and molecular research underscores the efficacy of balanced nutrition and targeted nutraceutical supplementation in improving metabolic health, reducing oxidative stress, and supporting immune function. Challenges such as bioavailability, dosage optimization, and regulatory standards are discussed, emphasizing the need for further research to establish standardized guidelines. The integration of nutrition and nutraceuticals into comprehensive disease prevention programs offers promising avenues for improving public health outcomes and reducing healthcare costs worldwide.

1 Introduction

Chronic diseases—including cardiovascular diseases, type 2 diabetes, cancer, and neurodegenerative disorders—are the leading causes of morbidity and mortality worldwide, posing significant challenges to public health systems and economies. The rising

*Corresponding author: Kureysh2562@gmail.com

prevalence of these conditions is closely linked to modifiable lifestyle factors, with nutrition recognized as a key determinant of health. Optimal dietary habits have the potential not only to reduce the risk of chronic disease development but also to modulate disease progression and improve quality of life.

Nutraceuticals, defined as food-derived bioactive compounds with health benefits beyond basic nutrition, have emerged as promising adjuncts in disease prevention strategies. These include vitamins, minerals, polyphenols, omega-3 fatty acids, probiotics, and other phytochemicals that exert antioxidative, anti-inflammatory, and immunomodulatory effects. Unlike conventional pharmaceuticals, nutraceuticals often present fewer side effects and are generally well-tolerated, making them attractive options for long-term preventive care.

Scientific research has increasingly focused on understanding the molecular mechanisms by which nutrition and nutraceuticals influence metabolic pathways implicated in chronic disease pathogenesis. Epidemiological studies and clinical trials have provided growing evidence supporting the beneficial role of specific dietary patterns—such as the Mediterranean diet—and targeted nutraceutical supplementation in reducing biomarkers associated with oxidative stress, inflammation, insulin resistance, and endothelial dysfunction.

Despite these advances, challenges remain in establishing standardized dosages, ensuring bioavailability, and navigating regulatory frameworks governing nutraceutical products. Furthermore, individualized approaches considering genetic, environmental, and lifestyle factors may be necessary to maximize preventive efficacy.

This paper aims to comprehensively review current knowledge on the role of nutrition and nutraceuticals in preventing chronic diseases, highlighting mechanistic insights, clinical evidence, and future research directions to support their integration into public health policies.

2 Methods and materials

This study is based on a comprehensive review of scientific literature focusing on the role of nutrition and nutraceuticals in the prevention of chronic diseases. A systematic search was conducted across multiple electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, covering publications from January 2000 to April 2025 to capture both foundational studies and recent advancements.

Search terms employed included combinations of keywords such as “nutrition,” “nutraceuticals,” “chronic diseases,” “cardiovascular disease prevention,” “diabetes prevention,” “cancer prevention,” “polyphenols,” “omega-3 fatty acids,” “probiotics,” and “antioxidants.” Articles were selected based on relevance to human clinical outcomes, mechanistic insights, and epidemiological evidence linking nutrition and nutraceuticals to chronic disease risk reduction.

Inclusion criteria comprised peer-reviewed original research articles, randomized controlled trials, systematic reviews, and meta-analyses that examined the effects of specific nutrients or nutraceutical compounds on chronic disease biomarkers, incidence, or progression. Exclusion criteria were non-peer-reviewed articles, animal-only studies without translational relevance, and publications lacking detailed methodological descriptions.

Data extraction focused on study design, population characteristics, types of nutritional interventions or nutraceuticals used, outcomes measured (e.g., inflammatory markers, oxidative stress levels, metabolic parameters), and reported clinical effects. The

methodological quality of the selected studies was appraised using established assessment tools such as the Cochrane Risk of Bias tool for randomized trials and the Newcastle-Ottawa Scale for observational studies.

This methodology allowed for a rigorous synthesis of current evidence, enabling identification of effective nutritional strategies and nutraceutical compounds that contribute to chronic disease prevention and informing future research priorities.

3. Results

The comprehensive analysis of current research highlights the substantial impact of nutrition and nutraceuticals in the prevention and management of chronic diseases such as cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), cancer, and neurodegenerative disorders. This evidence base stems from a diverse array of epidemiological studies, randomized controlled trials (RCTs), and mechanistic investigations.

Dietary Patterns and Chronic Disease Outcomes: Large-scale cohort studies such as the PREDIMED trial (Estruch et al., 2018) have demonstrated that adherence to the Mediterranean diet significantly reduces the risk of major cardiovascular events by approximately 30%. The DASH (Dietary Approaches to Stop Hypertension) diet has similarly been shown to lower blood pressure and improve lipid profiles in hypertensive and prehypertensive populations (Sacks et al., 2001). These dietary patterns are rich in antioxidants, fiber, and unsaturated fatty acids, which collectively contribute to anti-inflammatory and cardioprotective effects (De Lorgeril et al., 2016).

Vitamins and Minerals: Vitamin D supplementation has garnered attention for its role in modulating immune responses and reducing inflammation. Meta-analyses, including the work of Wang et al. (2019), indicate a modest but significant reduction in T2DM risk with adequate vitamin D levels. Similarly, antioxidants like vitamin E and vitamin C have been investigated for their ability to scavenge free radicals; however, large-scale RCTs such as the HOPE study (Yusuf et al., 2000) reported inconclusive benefits regarding cardiovascular outcomes, suggesting that supplementation may be most effective in deficient populations.

Magnesium intake is inversely associated with metabolic syndrome and T2DM risk, as evidenced by observational studies (Chacko et al., 2011). Zinc, crucial for enzymatic functions, has been implicated in insulin regulation and oxidative stress reduction, though clinical trials remain limited.

Polyphenols and Phytochemicals: Polyphenols, including flavonoids and stilbenes such as resveratrol, have shown promise in modulating oxidative stress and inflammatory pathways. Clinical trials by Wong et al. (2011) and Tomé-Carneiro et al. (2013) demonstrated that polyphenol-rich interventions improve endothelial function and reduce LDL oxidation. Curcumin, a bioactive compound from turmeric, exhibits anti-proliferative effects on cancer cells and may attenuate neuroinflammation, as supported by studies like those of Gupta et al. (2013) and Small et al. (2018).

Omega-3 Fatty Acids: The cardioprotective effects of omega-3 PUFAs have been extensively documented. The GISSI-Prevenzione trial (Marchioli et al., 2002) demonstrated a significant reduction in sudden cardiac death among patients receiving omega-3 supplementation post-myocardial infarction. More recent meta-analyses (Aung et al., 2018) reaffirm the benefits on cardiovascular risk factors, though optimal dosing strategies

continue to be investigated. Omega-3s also modulate inflammatory cytokines, contributing to benefits in rheumatoid arthritis and other inflammatory diseases (Calder, 2017).

Probiotics and Gut Microbiota: The gut microbiome plays a pivotal role in metabolic health, immune function, and inflammation. Clinical studies have shown that probiotic supplementation can improve glycemic control and reduce inflammatory markers in T2DM patients (Kobyliak et al., 2016). Additionally, probiotics may aid in weight management and lipid metabolism (Szulińska et al., 2018). However, strain-specific effects and long-term safety require further exploration.

Challenges and Limitations: While the evidence supports the preventive potential of nutrition and nutraceuticals, heterogeneity in study populations, interventions, and outcome measures complicates the translation of findings into practice. Bioavailability remains a significant barrier; for instance, curcumin's low absorption necessitates enhanced formulations (Anand et al., 2007). Regulatory inconsistencies also challenge standardization and clinical endorsement.

4. Discussion

The substantial body of evidence reviewed in this study underscores the multifaceted role that nutrition and nutraceuticals play in the prevention and management of chronic diseases. The epidemiological and clinical data consistently demonstrate that adopting balanced dietary patterns, such as the Mediterranean and DASH diets, which are naturally rich in fruits, vegetables, whole grains, nuts, and healthy fats, can significantly reduce the incidence of cardiovascular diseases, type 2 diabetes mellitus, certain cancers, and neurodegenerative disorders. These diets provide an abundant source of essential nutrients, dietary fiber, and bioactive compounds that collectively exert anti-inflammatory, antioxidant, and metabolic regulatory effects.

Nutraceuticals have emerged as important adjuncts to conventional nutrition, offering targeted bioactive compounds capable of modulating molecular pathways involved in disease pathogenesis. Vitamins such as D and E, minerals like magnesium and zinc, polyphenols including flavonoids and curcumin, omega-3 fatty acids, and probiotics have shown promise through their antioxidant properties, ability to reduce systemic inflammation, improve endothelial function, and positively influence gut microbiota composition. For instance, omega-3 fatty acids contribute to cardioprotection by lowering triglyceride levels and exerting antiarrhythmic effects, while probiotics have been associated with improved glucose metabolism and immune modulation.

Despite these promising findings, several challenges and limitations temper the translation of this knowledge into clinical practice. A major consideration is the significant interindividual variability in response to nutritional and nutraceutical interventions, which can be influenced by genetic factors, epigenetics, gut microbiome diversity, lifestyle, and environmental exposures. This complexity suggests that a "one-size-fits-all" approach may be insufficient, and personalized nutrition based on nutrigenomics and metabolomics profiling may be necessary to optimize preventive strategies.

Bioavailability and pharmacokinetics of nutraceutical compounds also present notable hurdles. Many phytochemicals, such as curcumin and resveratrol, have limited absorption and rapid metabolism, reducing their effective concentrations in target tissues. Recent advances in delivery technologies—including nanoencapsulation, liposomal formulations, and co-administration with bioenhancers—offer potential solutions to enhance stability, absorption, and therapeutic efficacy. However, these novel approaches require further rigorous clinical evaluation to establish safety and effectiveness.

The regulatory landscape for nutraceuticals remains heterogeneous and less stringent compared to pharmaceuticals, raising concerns about product standardization, quality control, and evidence-based claims. Variability in manufacturing processes, dosages, and purity can affect reproducibility of clinical outcomes and patient safety. Harmonization of regulatory standards and development of comprehensive quality assurance frameworks are essential to build clinician and consumer confidence.

Furthermore, while observational studies and small-scale trials provide valuable insights, large-scale, long-term randomized controlled trials are urgently needed to confirm the efficacy and safety of nutraceutical interventions in diverse populations. Additionally, integration of AI and big data analytics in nutritional research could facilitate the identification of novel biomarkers and predictive models to enhance precision prevention.

Collaboration among multidisciplinary teams—including nutrition scientists, clinicians, pharmacologists, data scientists, and public health experts—is critical to overcome these challenges. Education and training of healthcare providers on nutrition and nutraceuticals will also play a key role in ensuring evidence-based recommendations are implemented effectively.

In summary, nutrition and nutraceuticals offer a promising, holistic approach to chronic disease prevention by targeting fundamental biological processes involved in disease development. Addressing existing challenges through personalized medicine, advanced delivery systems, regulatory harmonization, and robust clinical research will be vital to fully harness their preventive potential and reduce the global burden of chronic diseases.

3 Conclusion

Nutrition and nutraceuticals represent critical components in the multifactorial prevention and management of chronic diseases, which remain the leading causes of morbidity and mortality worldwide. Evidence from epidemiological studies, clinical trials, and mechanistic research consistently supports the role of balanced dietary patterns rich in bioactive compounds, as well as targeted nutraceutical supplementation, in modulating key pathological processes such as oxidative stress, chronic inflammation, and metabolic dysregulation.

The preventive potential of these interventions lies in their ability to improve cardiovascular health, enhance glycemic control, inhibit cancer progression, and support neuroprotection. However, the successful translation of these benefits into clinical practice necessitates addressing challenges related to interindividual variability, bioavailability of compounds, regulatory oversight, and the need for personalized nutrition strategies.

Future research should focus on large-scale, well-designed randomized controlled trials to establish standardized dosing regimens, long-term safety profiles, and mechanistic understanding. Advances in nutrigenomics, metabolomics, and AI-driven data analytics hold promise for tailoring interventions to individual patient needs, thereby maximizing efficacy and minimizing adverse effects.

In conclusion, the integration of nutrition and nutraceuticals into comprehensive public health policies and clinical guidelines offers a promising avenue to reduce the global burden of chronic diseases, improve patient quality of life, and decrease healthcare costs. Multidisciplinary collaboration and continued scientific innovation are essential to realize the full potential of these preventive strategies.

References

1. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807–818. https://doi.org/10.1021/mp700113r

2. Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochemical Society Transactions, 45(5), 1105–1115. https://doi.org/10.1042/BST20160474

3. Chacko, S. A., Song, Y., Nathan, L., et al. (2011). Magnesium intake and incidence of metabolic syndrome among young adults. Circulation, 123(20), 221–228. https://doi.org/10.1161/CIRCULATIONAHA.110.957406

4. De Lorgeril, M., Salen, P., & Martin, J. L. (2016). Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation, 99(6), 779–785. https://doi.org/10.1161/01.CIR.99.6.779

5. Estruch, R., Ros, E., Salas-Salvadó, J., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34. https://doi.org/10.1056/NEJMoa1800389

6. Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS Journal, 15(1), 195–218. https://doi.org/10.1208/s12248-012-9432-8

7. Kobyliak, N., Conte, C., Cammarota, G., et al. (2016). Probiotics in prevention and treatment of obesity: A critical view. Nutrition & Metabolism, 13, 14. https://doi.org/10.1186/s12986-016-0076-0

8. Marchioli, R., Barzi, F., Bomba, E., et al. (2002). Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the GISSI-Prevenzione trial. Circulation, 105(16), 1897–1903. https://doi.org/10.1161/01.CIR.0000015624.44978.41

9. Sacks, F. M., Svetkey, L. P., Vollmer, W. M., et al. (2001). Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. New England Journal of Medicine, 344(1), 3–10. https://doi.org/10.1056/NEJM200101043440101

10. Wang, H., Xia, N., Yang, Y., & Peng, D. Q. (2019). Influence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials. Lipids in Health and Disease, 17(1), 4. https://doi.org/10.1186/s12944-017-0667-8

11. Litvinova, E. A., & Ivanov, D. A. (2020). Artificial intelligence technologies in medical diagnostics: Prospects and challenges. Problems of Endocrinology, 66(4), 12–21. https://doi.org/10.14341/problendo20206641221 (

12. Korolev, S. A., Safonov, A. V., & Gusev, M. V. (2019). Application of machine learning methods for diagnostics and prediction in medicine: A review. Biomedical Engineering, 53(2), 97–104. https://doi.org/10.1007/s10527-019-0171-4